louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03507231: Non-integrated Costs Increase Effectiveness of Incentives
Official title: Non-integrated Costs Increase Effectiveness of Incentives
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Control - No Incentive for Flu Vaccine
Direct Incentive
Indirect Incentive
Keywords: incentives
field study
vaccination
Lead sponsor: Carnegie Mellon University
Sponsor class: OTHER
Collaborators: name: Rutgers University
name: University of Pennsylvania
First posted: 2018-04-25
Enrollment: 12531
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators will test the hypothesis that the control (no incentive) condition will have the lowest vaccination rate, the main task condition will have a significantly higher vaccination rate while the indirect condition will have the highest vaccination rate.

Participants will be randomly assigned to one of the three message conditions and their vaccination records obtained from the university Occupational Health Department.

Detailed description: The investigators will send e-mails to a complete mailing list of faculty and staff at a university. Each recipient will be randomly assigned to one of three conditions: control, main task incentive or indirect incentive. Our main dependent variable will be whether or not participants decide to get vaccinated. The investigators will obtain their actual vaccination records from the university Occupational Health Department.

Within the e-mail message, participants will indicate whether or not they intend to get vaccinated. Intention serves as an indirect dependent outcome. Upon clicking to indicate their intention, participants are redirected to a page which gives further instructions on how to proceed.

Participants who vaccinate will be asked to complete a brief follow-up questionnaire to evaluate their experience with vaccination and (for those offered and incentive) to provide contact information to receive their payment.

Eligibility criteria: Inclusion Criteria:

* Must be faculty or staff at Rutgers University.

Exclusion Criteria:

-

Primary outcomes:
measure: Number of people vaccinated
timeFrame: Up to 5 months
Secondary outcomes:
measure: Intention to get vaccinated
timeFrame: Up to 5 months
Other outcomes:
Locations:
city: New Brunswick
country: United States
facility: Rutgers University
state: New Jersey
Study officials:
affiliation: Carnegie Mellon University
name: George Loewenstein, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Halpern SD, French B, Small DS, Saulsgiver K, Harhay MO, Audrain-McGovern J, Loewenstein G, Brennan TA, Asch DA, Volpp KG. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med. 2015 May 28;372(22):2108-17. doi: 10.1056/NEJMoa1414293. Epub 2015 May 13.
citation: Chapman GB, Li M, Colby H, Yoon H. Opting in vs opting out of influenza vaccination. JAMA. 2010 Jul 7;304(1):43-4. doi: 10.1001/jama.2010.892. No abstract available.
Clinical trial NCT06415331: Effectiveness of Conventional Therapy Plus Pulsed-Radiofrequency for Herniated Nucleus Pulposus
Official title: Comparison of The Effectiveness Between Conventional Therapy and Conventional Therapy Plus Pulsed-Radiofrequency in Herniated Nucleus Pulposus Patients at Dr. Saiful Anwar Hospital, Malang
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Herniated Nucleus Pulposus
Pain
Lead sponsor: Dr. Syaiful Anwar Hospital, Malang
Sponsor class: OTHER
First posted: 2024-05-16
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research was to study whether the additional application of a certain medical intervention making use of radiofrequencies (pulsed-radiofrequency) would reduce pain in patients with herniated disk.

Detailed description: Pain is an uncomfortable sensory and emotional experience that can affect quality of life. Low back pain (LBP) is one of the most common causes of pain, with herniated nucleus pulposus (HNP) being a common etiology. Pulsed radiofrequency (PRF) is a relatively novel technique that has shown promising results in many applications, including spinal pain conditions.

This quasi-experimental study aimed to compare pain levels between patients who underwent conventional therapy (CT) alone and CT plus PRF as management in patients with HNP. Pain severity was measured in the numeric rating scale before and 1 month after treatment.

Eligibility criteria: Inclusion Criteria:

* Having an established diagnosis of HNP
* Complaint present for at least the pas 3 months
* Experiencing pain intensity of 4 or greater on the numeric rating scale
* Capable of giving informed consent

Exclusion Criteria:

* Pregnant patients
* Presence of infection at the site of pulsed radiofrequency
* HNP with red flags.

Primary outcomes:
measure: Pain severity
timeFrame: 1 month after treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Malang
country: Indonesia
facility: Dr. Saiful Anwar Hospital
state: East Java
Study officials:
affiliation: Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia
name: Hana H Fachir, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01368731: Prophylactic Coagulation for the Prevention of Bleeding in Endoscopic Mucosal Resection of Large Sessile Colonic Polyps
Official title: Prophylactic Endoscopic Coagulation for the Prevention of Bleeding in Endoscopic Mucosal Resection (EMR) of Large Sessile Colonic Polyps: A Multi-centre, Randomised Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adenomatous Polyp of Large Intestine
Lead sponsor: Western Sydney Local Health District
Sponsor class: OTHER
First posted: 2011-06-08
Enrollment: 328
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The hypothesis of this study is that prophylactic coagulation therapy with coagulation forceps to visible vessels within the mucosal defect for colonic Endoscopic Mucosal Resection (EMR) will reduce the rate of delayed bleeding when compared with current established standard EMR technique.

Detailed description: Delayed bleeding from the site of the resection remains one of the most common complications following EMR, occurring in up to 12% of patients. The purpose of the study is to prevent such bleeding with the use of a technique known as: "coagulation therapy." This therapy involves using a small dose of heat energy that results in clotting(coagulation) of a blood vessel. It is already used widely in the stomach and we intend using this on a lower setting to blood vessels that are exposed after the resection.

Eligibility criteria: Inclusion Criteria:

* Patients referred to Westmead Hospital Endoscopy unit for endoscopic removal of a large sessile colonic polyp sized \>20mm
* Age \>18 years
* Able to give informed consent to involvement in trial

Exclusion Criteria:

* Pregnancy: currently pregnant or attempting to become pregnant
* Lactation: currently breastfeeding
* Taken clopidogrel within 7 days
* Taken warfarin within 5 days
* Had full therapeutic dose unfractionated heparin within 6 hours
* Had full therapeutic dose low molecular weight heparin (LMWH) within 12 hours
* Known clotting disorder

Primary outcomes:
measure: Presence of delayed bleeding
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Westmead
country: Australia
facility: Westmead Hospital
state: New South Wales
Study officials:
affiliation: Westmead Hospital - Endoscopy Unit
name: Michael J Bourke
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bahin FF, Naidoo M, Williams SJ, Hourigan LF, Ormonde DG, Raftopoulos SC, Holt BA, Sonson R, Bourke MJ. Prophylactic endoscopic coagulation to prevent bleeding after wide-field endoscopic mucosal resection of large sessile colon polyps. Clin Gastroenterol Hepatol. 2015 Apr;13(4):724-30.e1-2. doi: 10.1016/j.cgh.2014.07.063. Epub 2014 Aug 20.
Clinical trial NCT00274131: Long-term Administration Study of SND 919 Tablets in Parkinson's Disease
Official title: Long-term Administration Study of SND 919 Tablets in Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Parkinson Disease
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2006-01-10
Enrollment: 170
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of long-term treatment with pramipexole tablets (BI Sifrol®) in Parkinson's disease (phase III study).

Detailed description: The efficacy and safety of long-term treatment with pramipexole (BI Sifrol®) were evaluated in Parkinson disease patients in an open-label non-controlled design. The treatment was initiated at 0.125 mg bid (after breakfast and supper).

The dose was increased stepwise with due caution regarding the symptoms and safety of each patient, up to 1.5 mg tid (after each meal). The treatment period was set at 56 weeks, followed by a stepwise dosedecreasing period (maximum 4 weeks).

Study Hypothesis:

Comparison(s):

Eligibility criteria: Inclusion Criteria:

Patients with a diagnosis of Parkinson's disease (including juvenile parkinsonism)

(1) Patients meeting all of the following inclusion criteria

1. Patients of at least 20 years of age
2. In- or outpatients of either sex.
3. Patients in any stage on the modified Hoehn and Yahr severity scale

Exclusion Criteria:

* Patients with psychiatric symptoms such as confusion, hallucination, delusion, excitement, delirium, and abnormal behaviour.
* Patients with subjective symptoms derived from orthostatic hypotension.
* Patients with hypotension (systolic blood pressure \<100 mmHg)
* Patients with concomitant illness such as severe cardiac, renal, and hepatic disease
* Patients with a current or past history of epilepsy
* Pregnant, possibly pregnant, or lactating women
* Patients receiving any other investigational products or who have received any other investigational product within 6 months of the study.
* Patients who judged incompetent to give consent
* Others judged by the investigator or co-investigator to be ineligible as subjects.

Primary outcomes:
measure: UPDRS Part II (activities of daily living) total score UPDRS Part III (motor examination) total score
Secondary outcomes:
measure: UPDRS Part I (mentation, behaviour and mood) total score UPDRS Part IV (complications of therapy) total score UPDRS Part I-III total score UPDRS Part I-IV total score Modified Hoehn and Yahr scale score Global impression of efficacy
Other outcomes:
Locations:
Study officials:
affiliation: Nippon Boehringer Ingelheim Co., Ltd.
name: Boehringer Ingelheim Study Coordinator
role: STUDY_CHAIR
References:
Clinical trial NCT00194831: Correlation of Volumetric Brain Analysis With Development at 18 Months
Official title: Volumetric Brain Analysis in the Premature Brain: Correlation With Future Development
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Child Development
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2005-09-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Premature infants \< 1000 gram birthweight who are followed post discharge as part of standard clinical care

Brief summary: The study will correlate the volumes of the brain obtained from magnetic resonance imaging (MRI) scans done at term gestation for infants born prematurely who weighed less than 1000 grams at birth with their corresponding development at 18 months corrected age.


Eligibility criteria: Inclusion Criteria:

* All premature infants born \< 1000 grams who had MRI scans of the brain at term gestation

Exclusion Criteria:

* Any known genetic or chromosomal abnormalities

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York Presbyterian Hospital Weill Cornell
state: New York
Study officials:
affiliation: New York Presbyterian Hospital Weill Cornell
name: Jeffrey M Perlman, MB
role: STUDY_CHAIR
References:
Clinical trial NCT01146431: Memory During Inhalation Anesthesia Performed With or Without Bispectral Index (BIS) in Patients Undergoing Thyroidectomy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thyroidectomy
Lead sponsor: Catholic University of the Sacred Heart
Sponsor class: OTHER
First posted: 2010-06-17
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing general anesthesia for thyroidectomy

Brief summary: The purpose of this study is 1) to investigate whether the use of BIS as a guide to the administration of inhaled anesthetic (sevoflurane or desflurane) compared with the use of hemodynamic parameters (blood pressure and heart rate) would affect the occurrence of implicit memory and /or dreams recall and 2) to check whether the occurrence of implicit memory and/or dreams recall is related with MAC (Minimal Alveolar Concentration) of inhalational anesthetics and/or preoperative anxiety levels.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 70 years
* Class-ASA Physical Status I-II

Exclusion Criteria:

* Psychiatric or neurological disorders and/or hearing disorders
* Obesity (Body Mass Index \> 30)
* Drug addiction, alcoholism
* Patient with difficulty in understanding italian language and/or education level below middle school

Primary outcomes:
measure: Implicit memory
timeFrame: Approximately 24 hours after surgery
Secondary outcomes:
measure: Dreams recall
timeFrame: Approximately 5 minutes after awakening from anesthesia
measure: Explicit memory
timeFrame: Approximately 24 hours after surgery
measure: Dreams recall
timeFrame: Approximately 24 hours after anaesthesia
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Catholic University of Sacred Heart
Study officials:
References:
Clinical trial NCT01392131: Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)
Official title: Study to Evaluate Safety and Therapeutic Efficacy of a Nutritional Supplement 'Oncoxin' in Patients With Hepatocellular Carcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Hepatocellular Carcinoma
Keywords: Oncoxin
Safety of Oncoxin
Therapeutic efficacy of Oncoxin
Improvement of quality of life with Oncoxin
Survival benefit with Oncoxin
Lead sponsor: Clinical Research Organization, Dhaka, Bangladesh
Sponsor class: OTHER
First posted: 2011-07-12
Enrollment: 40
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Oncoxin is safe and results in improved survival in patients with hepatocellular carcinoma

Detailed description: To assess therapeutic efficacy and safety of Oncoxin in hepatocellular carcinoma

To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin

To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin

To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin

To see if there is improved survival in hepatocellular carcinoma patients after administration of oncoxin

Eligibility criteria: Inclusion Criteria:

* Patients with HCC irrespective of etiology, age, gender and status of underlying liver disease.
* Patients with HCC who are not suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy.
* Patients with HCC who have evidence of tumor metastasis
* Patients with HCC who are voluntarily unwilling to take established modalities of treatment i.e. surgery and/or chemotherapy.
* Patients with HCC in whom all possible treatment options have been exhausted.

Exclusion Criteria:

* Patients with HCC who are suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy.
* Patients with HCC who have no evidence of tumor metastasis
* Patients with HCC who are willing to take established modalities of treatment i.e. surgery and/or chemotherapy.
* Patients with HCC who are voluntarily unwilling to be included in the trial

Primary outcomes:
measure: Number of patients who have prolonged survival after receiving Oncoxin
timeFrame: 48 weeks
Secondary outcomes:
measure: Reduction in serum alpha-fetoprotein level and decrease in tumor size
timeFrame: 48 weeks
Other outcomes:
Locations:
city: Dhaka
country: Bangladesh
facility: Farabi General Hospital
Study officials:
affiliation: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
name: Mamun A Mahtab, MSc MD FACG
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04460131: Soluble ST2 and Cardiovascular Outcome
Official title: Association Between Soluble ST2 and Cardiovascular Outcome After Cardiovascular Surgery
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cardiovascular Disease
Lead sponsor: Nanjing Medical University
Sponsor class: OTHER
First posted: 2020-07-07
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive adults patients with heart disease who underwent cardiac surgery were included.

Brief summary: Cardiac surgery induces hemodynamic stress on the myocardium, and this process can be associated with significant cardiovascular morbidity and mortality. Soluble suppression of tumorigenicity 2 (sST2) is biomarker of myocardial remodeling and fibrosis; however, little is known regarding their potential association with cardiovascular events. This study aimed to investigate the release of sST2 and its association with cardiovascular events undergoing cardiac surgery.


Eligibility criteria: Inclusion Criteria:

* age ≥ 18 years
* Congenital heart disease requiring surgery
* Valvular heart disease requiring surgery
* Arrhythmia requiring surgery
* Aortic dissection requiring surgery
* Coronary heart disease requiring surgery

Exclusion Criteria:

* age \<18 years
* pregnancy
* severe renal dysfunction (creatinine \>200µmol/L)
* not capable of understanding or signing informed consent.

Primary outcomes:
measure: All-cause mortality
timeFrame: 30 days after surgery
Secondary outcomes:
measure: Heart failure
timeFrame: 30 days after surgery
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The first affiliated hospital of nanjing medical university
state: Jiangsu
Study officials:
affiliation: The First Affiliated Hospital with Nanjing Medical University
name: Yong-feng Shao
role: STUDY_CHAIR
References:
Clinical trial NCT00218231: Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
Official title: Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Schizophrenia
Tobacco Use Disorder
Keywords: schizophrenia
tobacco dependence
nicotine
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
First posted: 2005-09-22
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.

Detailed description: There is a high prevalence of cigarette smoking among people with schizophrenia and few smoking cessation interventions have been developed for these individuals. Bupropion is an antidepressant medication commonly used to treat smoking in smokers without psychiatric disorder. This study compares how smokers with schizophrenia and smokers without psychiatric illness respond to bupropion (0, 300 mg/day).

Participants will be randomly assigned to receive either bupropion or placebo. Study visits will occur after one-week treatment with placebo or bupropion. During study sessions, participants will come to the laboratory at 9 am and will remain abstinent in the laboratory for 5 hrs. Participants will then be assessed for craving and withdrawal symptoms after viewing and handling neutral cues and smoking cues. After that, participants will have a 90-min period to smoke, and smoking topography will be measured.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with schizophrenia or schizo-affective disorder
* Smokes between 20 and 50 cigarettes per day
* Moderate to high nicotine dependence score
* Interest in quitting smoking

Exclusion Criteria:

* Currently trying to quit smoking
* Seizure disorder or lowered seizure threshold due to anorexia, bulimia, head trauma, diabetes with insulin, or hypoglycemics
* Alcohol or drug use disorders
* Requires certain medications
* Pregnant or breastfeeding

Primary outcomes:
measure: Smoking behavior
timeFrame: after 5 hrs abstinence
Secondary outcomes:
measure: Adverse events
timeFrame: ongoing
measure: urge to smoke
timeFrame: after 5 hrs abstinence
measure: nicotine withdrawal symptoms
timeFrame: after 5 hrs withdrawal
Other outcomes:
Locations:
city: Providence
country: United States
facility: Providence VA Medical Center, RI
state: Rhode Island
city: Providence
country: United States
facility: Brown University
state: Rhode Island
Study officials:
affiliation: Brown University
name: Jennifer W. Tidey
role: PRINCIPAL_INVESTIGATOR
References: